December 2018

Micafungin and caspofungin pharmacodynamics in patients with candidemia

Candidemia is an important cause of health care-associated bloodstream infections. Appropriate antifungal therapy is crucial to reduce morbidity and mortality. A previous randomized clinical trial compared the clinical effectiveness of caspofungin 50 mg, micafungin 100 mg (M100), and micafungin 150 mg (M150) in treating invasive candidiasis and candidemia. M100 treatment success was non-inferior to caspofungin, while...

Author(s): Rawan Kassar, Janis Chang, Jerome Schentag and Coleman Rotstein